October 28, 2024 10:27 AM EDT StartupsDealsPharma AbbVie makes $1.4B acquisition of Alzheimer's biotech Kyle LaHucik Senior Reporter AbbVie said Monday it will pay $1.4 billion in cash to buy a Phase 1 Alzheimer’s and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
